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Identity 
HGNC (Hugo): MEN1 
Location: 11q13 
Note: Mutiple Endocrine neoplasia type 1: MEN1 (or 
Wermer syndrome) is an inherited predisposition to 
parathyroid, endocrine pancreas, pituitary, adrenal a d 
neuroendocrine tumors and segregates as an autosomal 
dominant disease with high penetrance. 
DNA/RNA 
Description 
The MEN1 gene spans 9 kb of the genome and is 
characterized by 10 exons; exon 1 and the 3' 832 bp of 
exon 10 are untranslated. The figure shows the general 
structure of the gene and some of germline mutations in 
patients affected by inherited MEN1 disease. 
Transcription 
A major 2,8 kb transcript is detected in all tissues 
 tested; a large 4,0 kb mRNA has been characterized in  
the pancreas and in the thymus but the 5' structure of 
the MEN1 gene and the promoter region remain to date
unknown; the 2,8 kb major mRNA could be initiated 
inside exon 1. 
Protein 
Description 
The MEN1 protein, menin, contains 610 amino-acids 
(67 kDa); contains two nuclear localization signals 
(NLS-1 and NLS-2) at the C-terminal end of the 
protein (exon 10), between amino-acids 479-497 for 
NLS-1 and 588-608 for NLS-2; this has been shown in 
vitro by deletion mutants construction with GFP-
coexpressing vectors. 
Expression 
Menin is widely expressed and mainly in testis and 
central nervous system; murine equivalent to MEN1 
has been cloned and most of the expression data have 
been confirmed in murine tissues, either in adults and
during embryogenesis by RNA in situ experiments. 
 
 
Structure of the MEN1 gene (The European Consortium on MEN1, 1997).
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Primarily localized in the nucleus and could translte in 
the cytoplasm during specific steps of the cell cycle. 
Function 
The MEN1 gene is a growth-suppressor gene, as shown 
by allelic deletion (LOH) in tumoral DNA from MEN1 
patients; menin has been showed to interact with the 
AP1 transcrition factor through his JunD component; 
this interaction involves mainly the first 40 amino-acids 
at the N-terminal end of menin and some specifics 
amino-acids in the central domain of the protein; Menin 
interacts specifically with JunD but with none of the 
other AP1 proteins, such as JunB, c-Jun, c-Fos and 
Fra1/2; among 11 missense mutations described in 
MEN1 patients, the authors reported that four of them 
decreased or abolished binding to JunD suggesting a 
separate domain between amino-acids residues 139 and 
142 could have a critical role in menin-JunD 
interaction; using mammalian two-hybrid assays, 
menin has been shown to repress JunD-mediated 
transcriptionnal activation but most of menin mutatn s 
with impaired JunD-binding properties lossed this 
inhibitory activity; strikingly, overexpression of normal 
or mutant menin in similar experimental assays led to 
the absence of repressional activity suggesting that
unknown factors could be involved in the menin-JunD 
interaction; new partners binding menin will be 
probably characterized in a near future and help us to 
understand the MEN1-related pathways. 
Homology 
No homology has been found to date either by 
comparison of primary sequence and secondary/tertiary 
structure of this protein with all known proteins 
involved in cellular physiology. 
Mutations 
Germinal 
Germline mutations in the MEN1 gene cause familial 
and sporadic multiple endocrine neoplasia type 1 
(MEN1) and the majority of mutations described 
predict premature protein truncation either by 
nonsenses and frameshifts in coding sequences; 
missense mutations have been identified in » 30% of 
cases and when characterized in sporadic cases, most of 
them need analysis of a large (>50) number of control 
individuals in order to exclude frequent 
polymorphisms; interestingly, all truncating mutations 
affect one or both NLS's and no missense mutations 
were observed inside NLS-1 and NLS-2; mutations are 
spread over the gene and most of them occur once in a 
single family; some mutations were observed in more 
than one family and when a common ancestor was 
excluded by haplotyping, these recurrent mutations 
might be accounted for 'hot-spots' in the MEN1 
sequence; most recurrent mutations are nonsenses and 
frameshifts in exons 2 and 10; for example, single base 
deletion occurs frequently at nucleotide 1650 in exon 
10 and has been related to the presence of an highly 
repetitive motif (CCCCCCCG) in this region inducing 
replication errors by slipped-strand mispairing; 
between 10 and 15% of sporadic MEN1 could be 
explained by de novo mutations, but this must be 
confirmed by an exhautive analysis of affected 
individuals and both parents. 
Implicated in 
Multiple endocrine neoplasia type 1 or 
Wermer syndrome 
Disease 
An inherited autosomal dominant predisposition to 
endocrine tumors, including parathyroids, endocrine 
pancreas, pituitary, adrenal glands, and the diffuse 
neuroendocrine tissues deriving from foregut; non-
endocrine tumors have been observed in some MEN1 
patients, including ependymoma, meningioma, 
cutaneous angiofibroma and lipoma, melanoma and 
rare visceral lesions such as rhabdomyosarcoma and 
leiomyoma; MEN1 is highly penetrant and more than 
90% of gene-carriers will present biological and/or 
clinical signs of the disease affter the fifth decade; 
around 5-10% of patients have an agressive disease 
before age 20 
No genotype-phenotype correlation were found to date 
in MEN1; nevertheless, most families with agressive 
NET have truncating mutations either in exons 2, 3, 9 
or 10 but no studies have been able to find statistical 
evidence of this putative correlation; recent 
investigations suggested that some MEN1 families 
could express only primary hyperparathyroidism, so 
called familial primary hyperparathyroidism (FIHPT), 
an allelic variant of MEN1; MEN1-related FIHPT 
appears as a benign disease but hyperplasia and/or 
adenoma occur in all parathyroid glands; recent data 
suggest that this variant could be associated to missense 
mutations in exons 4 to 7 of the MEN1 sequence; 
nevertheless, such correlations remain uncertain an do 
not have clinical implications in medical practice; the 
identification of germline missense mutations in exons 
4 to 7 must lead to an extensive biological and clinical 
screening of patients in order to exclude the occurrence 
of pancreatic and pituitary disease, as recently shown in 
a typical MEN1 family carrying a Leu264Pro in exon 
5; approximately 10-15% of MEN1 families do not 
show any mutation in the known part of MEN1 
sequence; clinical profile in these families do notdiffer 
from that of families with identified mutations and it is 
therefore possible that MEN1 mutations occur outside 
the coding sequence; deletion of part or full MEN1 
sequence has been also suggested as a rare mechanism 
of germline mutation. 
Prognosis 
It is mainly related to metabolic and organic 
complications of hormonal hypersecretion by tumoral 
cells (Zollinger-Ellison syndrome induced by 
gastrinoma, hyperinsulinism, hyperparathyroidism,  
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hyeperaldoseronism, Cushing syndrome, 
hyperprolactinemia, acromegaly; more than 30-50% of 
digestive neuroendocrine tumors and those localized in 
thymus and bronchi have a metastatic potential. 
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